Sanofi/€SAN

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Sanofi

Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Ticker

€SAN
Sector

Primary listing

PAR

Employees

82,878
Headquarters

Sanofi Metrics

BasicAdvanced
€98B
10.95
€7.34
0.44
€3.92
4.87%

What the Analysts think about Sanofi

Analyst ratings (Buy, Hold, Sell) for Sanofi stock.

Bulls say / Bears say

Sanofi exceeded expectations in the first quarter, with business operating income up 20.1% to €2.90 billion and Dupixent sales rising 20.3%. The company repurchased 72% of its €5 billion share buyback and reaffirmed full-year guidance despite global uncertainties.
The planned acquisition of Blueprint Medicines for up to $9.5 billion will broaden Sanofi’s immunology offerings beyond Dupixent by adding Ayvakit, which is already approved for systemic mastocytosis and expected to generate $2 billion in annual sales by 2030.
Sanofi’s RSV antibody Beyfortus achieved over €1.7 billion in its first full year of sales and still has considerable growth potential in the U.S. market, supporting Sanofi’s push into high-growth vaccine areas.
Dupixent accounts for nearly 40% of Sanofi’s total sales, leaving the company exposed to a major drop in revenue when its patent expires in 2031. Goldman Sachs notes Sanofi will need €11–12 billion from its wholly owned products to make up for this loss.
Sanofi’s experimental COPD drug itepekimab did not achieve its main goal in one of two Phase 3 AERIFY trials, causing Regeneron shares to drop nearly 9% and Sanofi’s U.S.-listed ADRs to fall 5%. This highlights the execution risks in Sanofi’s respiratory pipeline.
Blueprint Medicines is still unprofitable and faces rising competition from Cogent Biosciences, casting doubts over the costs to integrate and how quickly Sanofi’s up to $9.5 billion acquisition can turn profitable.
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.

Sanofi Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Sanofi Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €SAN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs